Stocks · News reference
On August 19, 2026, Mangoceuticals, Inc. (the "Company" or "MGRX") and Nuclea Energy Inc. ("Nuclea") mutually agreed to terminate that certain Business Combination Agreement, dated as of July 29,
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stock futures advanced on Friday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Thursday's higher close.
Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.
Mangoceuticals shares fall 12% after hours despite a $2.5 million strategic investment in its antiviral IP subsidiary.
Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined.